InMed Pharmaceuticals Inc (INM)

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company listed on NASDAQ under the ticker INM. The company focuses on developing prescription-based products in the United States, with research and development centered on cannabinoid-based pharmaceuticals. Its operations are organized into two segments: InMed Pharmaceuticals, which works on cannabinoid-based drug candidates, and BayMedica Commercial, which develops manufacturing technologies used to produce and sell rare cannabinoids for health and wellness applications.

The company’s pipeline includes INM-755, a cannabinol topical cream that has completed a Phase 2 clinical trial for epidermolysis bullosa, as well as INM-089, a small molecule designed as a selective dual CB1/CB2 agonist. Other programs include INM-900 for neurodegenerative diseases and INM-901 for Alzheimer’s disease. InMed also offers IntegraSyn, a biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids, along with rare cannabinoid products such as cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. Founded in 1981 and headquartered in Vancouver, Canada, the company adopted its current name in October 2014.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.